A Single Center, Randomized, Double-blind, Placebo-controlled Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Escalating Doses Of HSK7653 In Healthy Subjects
Latest Information Update: 11 Aug 2023
At a glance
- Drugs Cofrogliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Haisco Pharmaceutical Group
- 08 Sep 2020 New trial record
- 19 Aug 2020 According to a Haisco Pharmaceutical Group media release, in November 2017, HSK7653 was approved by the State Food and Drug Administration for Drug Clinical Trial Approval and this Phase I clinical trials was carried out in Peking Union Medical College Hospital in May 2018.
- 19 Aug 2020 Results presented in a Haisco Pharmaceutical Group media release.